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modeling the systems biology of drug-
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Abstract
Background: Drug-induced liver injury (DILI) is an adverse reaction caused by the intake of drugs of common use
that produces liver damage. The impact of DILI is estimated to affect around 20 in 100,000 inhabitants worldwide
each year. Despite being one of the main causes of liver failure, the pathophysiology and mechanisms of DILI are
poorly understood. In the present study, we developed an ensemble learning approach based on different features
(CMap gene expression, chemical structures, drug targets) to predict drugs that might cause DILI and gain a better
understanding of the mechanisms linked to the adverse reaction.
Results: We searched for gene signatures in CMap gene expression data by using two approaches: phenotype-
gene associations data from DisGeNET, and a non-parametric test comparing gene expression of DILI-Concern and
No-DILI-Concern drugs (as per DILIrank definitions). The average accuracy of the classifiers in both approaches was
69%. We used chemical structures as features, obtaining an accuracy of 65%. The combination of both types of
features produced an accuracy around 63%, but improved the independent hold-out test up to 67%. The use of
drug-target associations as feature obtained the best accuracy (70%) in the independent hold-out test.
Conclusions: When using CMap gene expression data, searching for a specific gene signature among the landmark
genes improves the quality of the classifiers, but it is still limited by the intrinsic noise of the dataset. When using
chemical structures as a feature, the structural diversity of the known DILI-causing drugs hampers the prediction,
which is a similar problem as for the use of gene expression information. The combination of both features did not
improve the quality of the classifiers but increased the robustness as shown on independent hold-out tests. The
use of drug-target associations as feature improved the prediction, specially the specificity, and the results were
comparable to previous research studies.
Keywords: CAMDA, Drug-induced liver injury, Hepatotoxicity, Drug safety, Systems biology, Machine learning,
Cmap, Drug structure
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Background
Drug safety is one of the main reasons of drug attrition
during development [1, 2]. Although the causes of drug
failure due to lack of safety are several, hepatic adverse
reactions are among the most important, particularly at
late drug development stages [3, 4]. Drug-induced liver
injury (also named DILI) is an adverse reaction caused
by the intake of drugs of common use that produces
liver damage. DILI has a relatively high incidence rate,
estimated to affect around 20 in 100,000 inhabitants
worldwide each year [5]. Many drugs ranging from pain
killers to anti-tuberculous treatments can cause DILI [6].
Despite DILI being one of the leading causes of acute
liver failure, the pathophysiology and etiology of DILI is
poorly understood and pinpointing the toxicity of com-
pounds in human liver remains a non-trivial task [7].
Several in-silico methods have been proposed to pre-
dict hepatotoxicity of drugs. Among these, machine
learning models trained using drug structural features
have shown a good accuracy [8–10]. Furthermore, in-
corporating gene- and pathway-level signatures from
transcriptomics data has shown a high predictive accur-
acy using Deep Neural Networks [11]. With the recent
increased interest on machine learning methods to pre-
dict drug-induced toxicity, the International Conference
on Critical Assessment of Massive Data Analysis
(CAMDA) has been organizing the Connectivity Map
(CMap) Drug Safety Challenge since 2018. The aim of
the challenge was to assess the state-of-the-art on DILI
prediction methods using different sources of data such
as transcriptomics data, chemical structures, and cellular
images. In the first edition (CAMDA 2018), the two
published studies applied various machine learning
methods for DILI prediction on the CMap gene expres-
sion data provided (in MCF7 and PH3 cell lines), obtain-
ing poor predictive results [12, 13]. Sumsion et al. [12]
evaluated 7 different classification algorithms and built a
soft-voting classifier that combined all classifiers. Still,
the accuracy results of the best performing classifiers
(random forest and soft-voting) were around 70%,
obtaining high sensitivity (77%) but low specificity (13–
19%). They also explored different strategies to improve
the results, such as normalizing gene expression data
across samples, feature selection methods, adjusting
class imbalance or improving the voting-based classifier.
Still, the improvement of the results with each of these
solutions was limited. Chierici et al. [13] used three deep
learning classifiers and compared them with random for-
est and multi-layer perceptron classifiers. They also
tested several strategies for balancing data and alterna-
tive train/test splits. However, the different strategies
gave an overall poor performance, in which the Mat-
thews correlation coefficient (MCC) values ranged from
− 0.04 to 0.21 in cross-validation and − 0.16 to 0.11 in
the independent hold-out test set. In both Sumsion et al.
[12] and Chierici et al. [13], the limited results were at-
tributed to having a small and highly imbalanced gold
standard of 190 drugs for training (160 DILI-causing)
and 86 drugs for an independent hold-out test. This
problem is still present in the current edition of
CAMDA (2019), as the size of the gold standard is still
limited. The organizers provided a gold standard (from
DILIrank dataset [14]) composed of 175 drugs for train-
ing and 55 for an independent hold-out test. They also
provided a dataset of CMap L1000 gene expression re-
sponses for 1314 compounds [15] (including the 230
drugs of the gold standard), the chemical structures
(SMILES codes) of the drugs and annotated images from
cell perturbation assays for a subset of 826 compounds
(156 from DILIrank) [16].
In this study, we implemented an ensemble learning
approach to predict drugs that can cause DILI in human
liver. We experimented the inclusion in the classifiers of
several features derived from transcriptomics, drug-
target associations and structural data either separately
or combined (Table 1). We investigated whether it was
feasible to find a DILI gene signature using phenotype-
gene associations, protein-protein interactions and gene
expression data. We observed that finding a meaningful
gene signature can improve the quality of the classifier
instead of using all landmark genes defined in the CMap
platform (i.e. the subset of 978 genes whose gene expres-
sion has been determined as informative enough to
characterize the whole transcriptome [15]). We also ana-
lyzed the accuracy of the prediction when using chem-
ical structures, drug-target information, and the
combination of these together with transcriptomics data.
We compared the quality of the classifiers made from
these features in a robust machine learning pipeline and
presented a list of conclusions that might serve as start-
ing points for further studies.
Methods
Gold standard data on drugs causing DILI
The CAMDA challenge provided the DILIrank dataset
[14] as the gold standard data of known DILI com-
pounds. DILIrank is a dataset that classifies the drugs in
three levels of DILI severity: “Most-DILI-Concern” when
the drug was withdrawn for DILI-related causes or la-
belled with severe DILI indication; “Less-DILI-Concern”
when the drug was labelled with mild DILI indication or
adverse reactions; and “No-DILI-Concern” when no
DILI was indicated in any of the labelling sections.
Moreover, these levels of severity were verified using
the standardized clinical causality assessment system,
and the drugs that were not meeting the expected se-
verity were reclassified as “Ambiguous-DILI-Concern”.
Among all the drugs categorized in DILIrank, the
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CAMDA challenge provided data for 230 drugs: 37
Most-DILI-Concern, 87 Less-DILI-Concern, 51 No-
DILI-Concern and 55 Ambiguous-DILI-Concern. Add-
itionally, the US Food and Drug Administration clas-
sified the remaining 55 Ambiguous-DILI-Concern
drugs as DILI or No-DILI-Concern. These 55 drugs
served as a dataset for an independent hold-out test,




The gene expression data used in this study was gath-
ered from the CMap L1000 Assay Platform [15]. The
L1000 Assay Platform provides more than one million
gene expression profiles from a wide range of cell lines
treated with different drugs at different doses and treat-
ment durations. Assuming that gene expression is highly
correlated, the Platform features a subset of approxi-
mately 1000 landmark genes to derive profiles that serve
to infer the expression of the rest of genes. We used
CMAP L1000 level 5 data which contained z-score
values corresponding to the normalized differential ex-
pression between the drug treatment and control across
different conditions.
Genes associated to DILI related phenotypes
We manually curated a list of phenotypes closely re-
lated with DILI and identified the genes associated
with these phenotypes using the DisGeNET database
v6.0 [17] (Table 2). We restricted disease-gene associ-
ations solely to expertly curated repositories: UniProt
[18], the Comparative Toxicogenomics Database
(CTD) [19], ORPHANET [20], the Clinical Genome
Resource (CLINGEN) [21], the Genomics England
PanelApp [22] and the Cancer Genome Interpreter
(CGI) [23]. We kept only the phenotypes with at least
10 curated gene associations. The full list of associa-
tions between DILI phenotypes and genes can be
found at Supplementary Table 1.
Drug chemical structure
The chemical structures of the drugs considered in the
study were provided by the CAMDA challenge in the
form of Simplified molecular-input line-entry system
(SMILES) string. In order to use this type of data, we
calculated the similarity between all compounds, creat-
ing a matrix of chemical similarity. Specifically, we used
the R package RxnSim [24] to calculate the similarity
matrix using the Tanimoto distance [25]. We used the
function ms.compute.sim.matrix (default parameters),
which identifies the fingerprints of the SMILES and
computes the fingerprint similarity between pairs of
SMILES. The full list of SMILES is provided in Supple-
mentary Table 2, and the matrix of Tanimoto similarity
between SMILES in Supplementary Table 3.
Drug-target association
The targets of the compounds considered in the study
were retrieved from three different databases: DGIdb
[26], HitPick [27] and SEA [28]. DGIdb gathers validated
drug targets, whereas HitPick and SEA additionally pro-
vide predicted targets based on chemical similarity. We
used the names of the drugs to retrieve the drug-protein
associations from DGIdb, whereas the SMILES strings
were used in the case of HitPick and SEA web servers.
Any drug-protein pair that had been provided either by
the database or predicted to interact by the web servers
were included among the drug-target associations. This
implies that there are no differences between validated
and predicted targets. However, this allowed us to in-
crease the number of input drugs and extended the po-
tential recall of our method. After collecting all targets, a
matrix was created with all the drugs in rows and all the
target proteins in columns. The cells of the matrix had
values 1 (if the drug targeted the protein) and 0 (other-
wise). There are three drugs from the DILIrank dataset
(alaproclate, fluvastatin and tenofovir) and two drugs
from the independent hold-out test dataset (entecavir
and vinorelbine) without any targets in these databases.
These drugs have not been used neither for training nor
for testing when using drug targets as features. The full
Table 1 Summary of the features used in the classification task
Type of feature Name Description
Gene expression features Landmark genes 978 genes directly measured from the L1000 datasets
DisGeNET DILI genes Curated genes associated to 9 phenotypes related with DILI from DisGeNET database
GUILDify DILI genes Genes associated through the protein interactions network to 6 phenotypes related
with DILI using GUILDify
DILI landmark genes 66 landmark genes selected using non-parametric test for each gene across all samples
of Most/Less- vs. No-DILI-Concern drugs (P-value< 0.05)
Structural features SMILES Line notation describing the chemical structure of drugs
Drug target genes Set of targets 1664 drug targets retrieved from DGIdb, HitPick and SEA
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list of drug-target associations is provided in Supple-
mentary Table 4.
Prediction pipeline
We created a supervised machine learning pipeline (Sup-
plementary Fig. 1) to generate predictions using the fea-
tures described in Table 1. The pipeline was
implemented using the R package caret [29]. Briefly, we
used two classifiers: the random forest classifier and the
gradient boosting machine. We limited the number of
classifiers because CAMDA had a limited number of in-
dependent hold-out test trials, and we tested many dif-
ferent features. Thus, we focused on two tree-based
ensemble methods that have been widely employed in
previous research [30–32].
We created a balanced dataset containing the 30% of
the data for testing and the rest for training. The original
dataset is comprised of 124 drugs labelled as DILI (37 as
Most-DILI-Concern and 87 as Less-DILI-Concern) and
51 labelled as no DILI. To create a balanced testing
dataset, as there were less drugs labelled as no DILI, we
randomly picked the 30% of the 51 no DILI drugs (15
drugs), and the same number of DILI drugs, maintaining
the ratio of Most-DILI-Concern (29.8%) and Less-DILI-
Concern (70.2%): 4 Most-DILI-Concern drugs (the
29.8% of 15) and 11 Less-DILI-Concern drugs (the
70.2% of 15). The rest of the drugs (109 DILI drugs and
36 no DILI drugs) were used for creating multiple train-
ing datasets. In order to have balanced training datasets,
while at the same time, to cover as many DILI drugs as
possible, we created 10 different training datasets. All of
them have the same 36 no DILI drugs (corresponding to
the 70% of the initial 51 drugs), but each of the training
dataset has a different subset of DILI drugs. Accordingly,
among the 109 DILI drugs, we picked randomly 11
Most-DILI-Concern drugs (29.8% of 36) and 25 Less-
DILI-Concern (70.2% of 36) (see Supplementary Fig. 1
for a schematic representation of the procedure, and
Table 2 List of manually selected phenotypes related with DILI. The selected phenotypes were required to have 10 gene
associations or more. The genetically redundant phenotypes have been merged in the same term. The empty cells correspond to
phenotypes for which the expansion through the network using GUILDify was not functionally coherent
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Supplementary Table 5 for a detailed list of the number
of drugs used in each step).
The 10 training datasets were used to train 10 different
models. For each model, the hyperparameters of the ma-
chine learning classifier were tuned using the functions
trainControl and train from the R package caret [29].
Specifically, we used a 10-fold cross-validation approach,
allowing resampling of the training set to avoid overfit-
ting. The train function automatically tests different
models using several combinations of hyperparameters
and selects the model with higher accuracy. The 10 fit-
ted models were evaluated using the testing dataset,
obtaining a series of measures (accuracy, precision, sen-
sitivity, specificity, F1-score, MCC) that indicate the
quality of the model. Lastly, the testing set predictions of
the 10 models were used as features to train a random
forest classifier that combined them into a final model.
The final model was used to classify the drugs of the in-
dependent hold-out test dataset into DILI drugs and
non-DILI drugs.
Results
L1000 connectivity map data hints at transcriptomic
heterogeneity of DILI compounds
CMap collects gene expression signatures obtained from
cell lines upon treatments with different drug concentra-
tions and durations. The treatment dose ranges from the
drug’s reported effective concentration, if known, to a
relatively high concentration of 10 μM or more, often
adopted in high-throughput cell based screens [33]. In
order to include perturbations possibly leading to adver-
sities or able to challenge cells adaptive mechanisms, we
decided to focus on drugs tested at the highest concen-
tration and for the longest treatment duration (i.e. high
coverage, high dose, and long treatments). Therefore, we
focused only on the samples treated at 10 μM dose and
at least for 24 h. Furthermore, as DILI phenotypes are
mainly originated and affecting the liver, we decided to
study only those sets collected from the cell line “Pri-
mary Human Hepatocytes” (PHH), as to date, it is the
most specific in vitro cellular model for liver. This pro-
duced a final set of samples with a single dose-time
point from 51, 87, and 37 drugs annotated as No-DILI-
Concern, Less-DILI-Concern, and Most-DILI-Concern,
respectively.
As an initial exploratory analysis of the training data
set, we analyzed the transcriptional response of the
different drugs using k-nearest neighbor clustering
algorithm (k = 3,4,5) (Supplementary Fig. 2). In the plot,
we cannot distinguish the different groups of drugs
based uniquely on gene expression and thus a more spe-
cific gene signature is needed. Indeed, we applied the
landmark genes signature as a feature for a machine
learning algorithm (as described in the Methods section)
obtaining a mean accuracy of 52% in the testing set and
43% in the independent hold-out test set (Fig. 1). Per-
haps more relevant are the low values of MCC (0.04
in the testing set and − 0.09 in the independent hold-
out test set), which indicates that the level of expres-
sion of landmark genes (978) from CMap is not a
predictor of DILI. In view of these results, we decided
to look for alternative chemical structure, gene and
phenotype based signatures. In the following sections,
we explain the different strategies we developed to
characterize DILI (Fig. 2).
Using phenotype-gene associations highlights potential
connections between DILI, cirrhosis and drug induced
hepatitis
To characterize genes involved in DILI that could be
used as a gene signature in the classifier, we searched for
specific genes associated with DILI looking into
phenotype-genotype data. These data contain genes that
have been described as associated to the pathophysiology
or etiology of DILI, and therefore represent a suitable
source to develop a list of genes representative of DILI.
We manually curated a list of phenotypes closely related
with DILI and identified the genes associated with these
phenotypes using the DisGeNET database v6.0 [17]
(Table 2, Supplementary Table 1). Although we might
expect them to be genetically similar, the overlap of
genes between the different DILI phenotypes is very
small (Supplementary Fig. 3). This fact reflects the diver-
sity of the phenotypes considered and the challenge as-
sociated to predict DILI based solely on gene expression.
Once defined the set of genes for the different DILI-
related phenotypes as annotated in DisGeNET, we re-
trieved their gene expression data from the CMap L1000
Assay Platform. For each DILI-related phenotype, we
trained an independent machine learning model using
the expression levels of their genes as features. The aver-
age accuracy obtained for the models of all DILI-related
phenotypes is 57% in the testing set. This means that for
some specific phenotypes the accuracy was higher than
57%. Therefore, we inspected the results for all pheno-
types separately, observing those with higher accuracy
than others (Fig. 3). The phenotypes “Biliary cirrhosis”,
“Hepatitis, Drug-Induced” and “Liver cirrhosis” stand
out for having an accuracy between 64 and 69% and
values of precision, sensitivity and specificity above 50%,
and MCC above 0.3. It is worth noting that “Biliary cir-
rhosis” is the phenotype less genetically similar to the
rest, i.e. the lowest number of shared genes (Supplemen-
tary Fig. 3) yielding the best results of prediction.
Among the genes associated with these phenotypes,
some of them have been associated to hepatotoxicity by
a previous study of Peng et al. (2019) [34], where 145
hepatotoxicity-related genes were identified. “Biliary
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cirrhosis” contains 5 hepatotoxicity-associated genes,
“Hepatitis, Drug-Induced” has 27 and “Liver cirrhosis”
25 (Supplementary Table 6).
Incorporating protein-protein interactions to find a DILI
signature does not improve the results of phenotype-
gene associations
Our current knowledge of genotype-phenotype associa-
tions is still incomplete and therefore we might miss
relevant genes associated to DILI. It has been demon-
strated that the products of disease-associated genes
tend to be highly connected in the protein-protein
interaction network, forming the so-called disease mod-
ules [35, 36]. Based on this fact, network-based
prioritization methods exploiting the topology of the
protein-protein interactions network have been success-
fully applied to discover and prioritize novel disease-
gene associations [37].
Using the network-based prioritization web server
GUILDify [38], we extended the current knowledge of
disease-associated genes obtained from DisGeNET (see
above in the previous section). GUILDify uses the genes
associated with DILI-related phenotypes as seeds for an
algorithm that scores the proteins of the protein-protein
interaction network based on their topological closeness
with the seeds. Then, it selects the top-ranking genes
using a functional-coherency-based cut-off: non-seed
genes are iteratively included in the top-ranking set pro-
vided that they maintain the functional coherency of the
seed genes (they are involved in similar biological
Fig. 1 Results of the Classifiers in the testing set and the independent hold-out test set. The machine learning algorithm used was a Random
Forest. The features that were used in the models of DisGeNET, GUILDify, DisGeNET+SMILES and GUILDify+SMILES are only from the phenotype
“Biliary cirrhosis” (C0023892). The results of using different phenotypes are given in the Fig. 3. The results for gradient boosting machine classifier
are given in the Supplementary Fig. 8
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functions). The numbers of the new associations with
the DILI-related phenotypes are listed in Table 2.
After obtaining the new list of phenotype-gene associ-
ations, we retrieved their gene expression data from the
CMap L1000 Assay Platform as shown before (i.e. PHH
cell line with 10 μM dose and treatment duration of 24
h) and used the expression level of these genes as input
feature to the machine learning classifier. As shown in
Fig. 1 the predictive capacity of the classifiers in the
training set dropped with regards to the approach de-
scribed in Section 2, obtaining similar values to that of
when using the 978 landmark genes albeit with a slightly
higher specificity (see results by phenotype at Supple-
mentary Fig. 4).
Differential comparison of gene expression does not
produce a robust DILI signature
To investigate the extend the transcriptomics data on
drugs with known DILI status could be used to extract a
DILI gene signature, we retrieved the normalized
differential expression data of the genes in PHH cell line
(10 μM dose and treatment duration of 24 h). For each
gene, we checked whether the expression values were
significantly different between DILI and No-DILI-
Concern drugs. Therefore, for each landmark gene, we
applied a two-sided Wilcoxon test, a non-parametric test
comparing the expression of the gene in the samples of
DILI-Concern drugs and No-DILI-Concern drugs. We
selected the genes with a P-value lower than 0.05,
obtaining a gene signature composed of 66 genes (re-
ferred from now on as DILI landmark gene signature)
(see Supplementary Table 7). We chose to use marginal
P-values, focusing on the ranking of genes and aiming to
capture the broad transcriptomic DILI signal.
Consistent with the known heterogeneity of tran-
scriptomics response in hepatotoxicity, the genes in the
identified signature were typically perturbed only in a
small subset of the samples, failing to represent a com-
mon response that could be explained by gene expres-
sion changes (Fig. 4). However, while the gene
Fig. 2 General scheme of the processing of the different features
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expression of the 1000 landmark genes yielded an accur-
acy of 52% (43% in the independent hold-out test set),
using only the 66 selected genes increased the accuracy
to a 69% (55% in the independent hold-out test set). The
discrepancy between the testing and independent hold-
out test sets can be attributed to the gene expression sig-
nature likely fitting to the underlying biology of the
training set compounds rather than representing a
generalization across all potential DILI compounds. We
performed a functional enrichment analysis [39] using
Gene Ontology to further investigate the biological pro-
cesses of these genes.
The functional enrichment analysis of the 66 genes did
not yield specific functions significantly associated with
the genes. This indicates that, even though the selected
genes improve the capacity of the classifiers to predict
DILI-causing drugs in comparison with using all the
landmark genes, they are not related with specific bio-
logical processes. Additionally, we compared these 66
genes to the 145 identified by Peng et al. (2019) [34] as
associated to hepatotoxicity (Supplementary Table 6).
Only 4 genes were highlighted as hepatotoxic in Peng
et al’s study. Therefore, although the approach suc-
ceeded at improving the predictive capacity of the
classifiers, the results could lead to overfitting by the
available data, as the gene signature is not related to any
specific biological function.
The use of chemical structure and drug-target
associations increases the prediction accuracy
Besides using gene expression data, we investigated the
incorporation of orthogonal information derived from
chemical structure of the drug and its targets. The
chemical structure and the molecular descriptors of the
drugs have already been used in machine learning
models, showing a fair predictive capacity [10]. Here, we
used the Tanimoto similarity between the molecular fin-
gerprints of all the drugs in the dataset. First, we plotted
the similarity between Most-DILI-Concern and No-
DILI-Concern drugs in the dataset in a histogram (Sup-
plementary Fig. 5). We observed that drugs of the same
group did not have higher similarity among them than
with other groups. Furthermore, No-DILI-Concern
drugs have higher similarity between themselves (mean
0.24) than Most-DILI-Concern drugs (mean 0.18). This
indicates that there is a considerable structure hetero-
geneity within the Most-DILI-Concern group of drugs,
which complicates the prediction using chemical
Fig. 3 Results of the classifier based on gene sets from DisGeNET DILI phenotypes in the testing set. The machine learning algorithm used was
Random Forest. Each row corresponds to the mean performance of 10 models trained using the PHH gene expression of the genes associated to
each DILI phenotype. The “Mean” row corresponds to the average performance of each metric for all the phenotypes
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structure. But this also suggests that probably, when
combining this feature with other types of features (i.e.
transcriptomics), the prediction may improve.
Eventually, we obtained a higher prediction accuracy
when combining chemical structure and CMap than
when applying them separately (Fig. 1). When using solely
chemical structure as feature for the machine learning
classifiers the average accuracy was 65% (MCC of 0.31) in
the test set and 55% (MCC of 0.17) in the independent
hold-out test set. In contrast, when combining chemical
structure with transcriptomics data, the prediction of the
classifier in the independent dataset improved. This is re-
markable when combining it with the DILI landmark gene
signature derived from the nonparametric test: the average
accuracy is maintained at 63% (MCC of 0.26) in the test
set and increases to 67% (MCC of 0.40) in the independ-
ent hold-out test set (Fig. 1).
Next, we explored the use of drug-target associations
as a feature to predict DILI. We considered any drug-
protein pair that had been reported in DGIdb [26] or
predicted to interact by HitPick [27] or SEA [28]. We in-
tegrated targets from these databases, creating a matrix
containing drugs and target proteins (see Methods). We
analyzed the percentage of DILI drugs, no-DILI drugs
and drugs from the independent dataset associated to
the targets in the matrix (see Supplementary Table 8
and Supplementary Fig. 6). We observed that some
proteins are mostly targeted by one type of drug, hypo-
thetically facilitating the classification of drugs. For in-
stance, proteins such as CYP2C9 and CYP1A2, that are
Fig. 4 Transcriptomics signatures of the DILI landmark genes. Gene expression (as Moderated Z score) of the DILI landmark genes (selected using
a two-sided Wilcoxon rank sum test, P < 0.05) in PHH cells, for Most-DILI-Concern and No-DILI-Concern drugs. The gene expression lower than
|1.5| is colored white
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associated with a higher proportion of DILI drugs than
to no-DILI drugs, have been previously associated to
hepatotoxic effects [40, 41]. Thus, we used the matrix
as a feature for the machine learning classifiers,
obtaining an accuracy of 57% (MCC of 0.15) in the
testing set and 70% (MCC of 0.35) in the independent
hold-out test set (Fig. 1). The increase of accuracy in
the independent dataset is explained by the high spe-
cificity (i.e. no-DILI drugs are predicted correctly) in
contrast with the low sensitivity (i.e. DILI drugs are
not predicted correctly).
Hepatocyte cell lines provide a better context for DILI
prediction than using combined expression from different
cell lines
In the previous sections, when using CMap gene expres-
sion data, we selected only the samples from the PHH
cell line with 10 μM dose and treatment duration of 24
h. We focused on the drug response in liver cells. How-
ever, the data of CMap tends to have a high variation of
expression between samples even for the same gene.
Therefore, to avoid biases caused by the use of unrelated
samples, we experimented using only the top correlated
samples for each drug. This consists in computing the
correlation between all the samples exposed to a drug
(even if they are from different cell lines, doses and
treatment durations) and selecting the ones that are
more correlated between themselves. We selected the
pairs of samples from different cell lines that have a
Pearson correlation above 0.5, or otherwise we kept the
pair that was more correlated. To use a correlation
threshold of 0.5 guarantees that the expression of the
samples selected is consistent enough across several cell
lines. Once the correlated samples are selected, we use
the median gene expression as feature. Although the ap-
proach was theoretically promising, the prediction ac-
curacies with the use of correlated samples are generally
worse than using specific conditions, obtaining MCC
values ranging from − 0.12 to 0.21 (see Supplementary
Fig. 7). This indicates that we are still getting noise from
correlated samples and that, even if there are some sam-
ples that could be less reliable, the use of specific liver
conditions in gene expression seems to be the best ap-
proach for the prediction of DILI-Concern drugs.
Discussion
In this work, we aim to predict DILI applying machine
learning algorithms using a range of orthogonal types of
data as input features. Indeed, we explored the use of
gene expression data from different sets of selected
genes (i.e. landmark, DisGeNET and GUILDify sets)
alone and in combination with drug-centric information
in the form of structural similarity (Tanimoto scores)
and protein targets (see Table 1 for a brief description of
the features). Furthermore, we observed that the DILI
landmark gene signature identified by a non-parametric
test (Wilcoxon test) of differential expression between
DILI and no-DILI samples from PHH cell line consti-
tuted a better feature set than the whole landmark genes
in CMap.
The genes in the identified DILI landmark gene signa-
ture were typically perturbed only in a small subset of
the samples, failing to represent a response that could
solely be explained by gene expression changes (Fig. 4).
This finding is consistent with the known heterogeneity
of transcriptomics response in hepatotoxicity [42]. Also,
it could be related with the diversity of outcomes of the
different compounds (i.e. acute, chronic or idiosyncratic
reactions). Nevertheless, as we were using data from the
training set to obtain the signature, the results could
lead to overfitting, which would explain why the accur-
acy of the prediction in the independent hold-out test
worsened. Moreover, the drugs of the independent hold-
out test set were originally flagged as ambiguous and for
this reason are probably a more challenging set to clas-
sify. Also, the independent hold-out test could be unbal-
anced, worsening the results despite the classifier being
trained on a balanced dataset.
We also took advantage of functional information of
the genes involved in drug response, and evaluated gene
expression related to liver phenotypes involved in drug
response using DisGeNET resource [17]. In the same
way as before, limiting the number of genes to a specific
signature (the genes associated to a DisGeNET pheno-
type) also constituted a better feature set than the whole
landmark genes in CMap, but still failed to represent the
whole response. The best accuracy was achieved by the
phenotype “Biliary Cirrhosis”, which is one of the final
stages of DILI. Since we used the data from the highest
dose and time point, it makes sense that extreme pheno-
types related with liver cirrhosis are better predictors.
Perhaps, the biliary component is also important for the
predictor. For further studies, it would be interesting to
focus on lower doses in order to capture earlier events
and not the final extreme phenotype. It is also important
to remark that the gene expression signatures come
from an in vitro model (primary cells, but still with the
limitations of 2D, dedifferentiation, etc.). As we applied
gene signatures derived from human data, this could
have affected the results.
Additionally, we expanded the phenotype-gene associ-
ations retrieved from DisGeNET incorporating protein-
protein interactions data from GUILDify. By applying
GUILDify we could expand the number of genes associ-
ated with DILI-related phenotypes by incorporating
those connected by the underlying protein interactome.
Surprisingly, the quality of the prediction when adding
protein interactions decreased with respect to using
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solely phenotype-gene associations. Our hypothesis is
that when expanding the number of genes using GUIL-
Dify, (i.e. obtaining larger gene signatures), the intrinsic
data noise from the CMap dataset is increased as well,
hence hampering the prediction. Still, we think that
using protein-protein interactions to extend our infor-
mation on DILI targets and hepatotoxicity-associated
genes without using gene expression data could be an
interesting feature to explore in the future.
After working with transcriptomics data from CMap,
we observed variability of the results depending on the
pre-processing of the samples. We tried two different
strategies that led to different results: (i) focusing on
samples from a unique cell line and dose-time point for
each drug, and (ii) selecting the most correlated samples
for each drug. This is by no means comprehensive and
various possible strategies such as using other cell lines
and dose-time points, or discarding the samples with
low correlation between replicas (‘distil_cc_q75’ < 0.2)
and selecting the sample with highest transcriptional ac-
tivity score [43] could be investigated further.
When focusing on samples from a unique cell line and
dose-time point, we decided to use the highest concen-
tration and the longest treatment duration. In this way,
we were including perturbations possibly leading to ad-
versities for the adaptive mechanisms of the cells. We
acknowledge that focusing on increased exposure of the
drug to characterize DILI is a relatively strong assump-
tion as there could be certain compensatory mechanisms
kicking in after a while depending on the specific com-
pound and cell line. Nevertheless, we think that employ-
ing the highest dose at the longest time of exposure is
likely to be a fair representation of the effect of DILI in
the cells after the administration of the drug.
Apart from the limitations inherent in the CMap data-
set, we detected: (i) an important genetic diversity
between the diverse DILI-related phenotypes from
DisGeNET (Supplementary Fig. 3), and (ii) a great struc-
tural diversity between the drugs reported as DILI-
Concern (Supplementary Fig. 5). Both aspects hamper
the prediction of DILI-Concern drugs when using
transcriptomics or structural features separately and
encouraged us to use and combine other sources of
information.
When considering both transcriptomics and struc-
tural features together, we observed a similar predict-
ive power of the classifiers, but a general increase
when validating the classifiers with an independent
dataset (Fig. 1). The most accurate classifier was gen-
erated by the Random Forest algorithm using a com-
bination of features that included the chemical
similarity of drugs (Tanimoto coefficient calculated
using SMILES) and gene expression from the land-
mark genes selected with a non-parametric test (DILI
Landmark + SMILES). Under a benchmark scenario,
the classifier was able to separate DILI-Concern drugs
better than No-DILI-Concern drugs (accuracy 63%,
sensitivity 54% and specificity 72%). Furthermore, on
the independent dataset of ambiguous-DILI drugs re-
labelled by the FDA, it reached an accuracy of 67%,
the second highest among the different classifiers. In
the future, it would be interesting to use the drug
structures directly as features (without using their
similarities) and to combine them with the other
types of features, as there might be critical informa-
tion within the actual molecular details of the drugs.
Lastly, we explored if the use of drug-target associa-
tions could be useful to predict DILI-causing drugs. The
results showed that the targets of most DILI drugs were
related with hepatoxicity (Supplementary Fig. 6). The
use of drug-target associations as a feature produced an
accuracy of 57% in the testing set and 70% in the inde-
pendent dataset. The observed accuracy on the inde-
pendent dataset is in line with 72.5% sensitivity and
72.7% specificity of the computational model developed
by Zhang et al. as well as with the 70.9% accuracy ob-
tained by Hong et al. on the bootstrapped data set,
highlighting the current limitations in predicting drug
induced injury [8, 9].
When comparing the results with the publications of
the previous CAMDA 2018 edition [12, 13], we still do
not observe a clear improvement on the prediction of
DILI. Although the data provided is much more exten-
sive, including gene expression data from more cell lines,
the gold standard is still very reduced and unbalanced.
The results in terms of accuracy in the training set are
very similar to the ones obtained by Sumsion et al. [12],
but worse when looking at the independent hold-out
test. This is probably due to the fact that the current in-
dependent dataset is based on “Ambiguous-DILI” drugs,
making the task more challenging. In terms of MCC
values, our results (ranging from − 0.05 to 0.39 in cross-
validation and − 0.09 to 0.40 in independent hold-out
test) are slightly better than the ones reported in Chierici
et al. [13] (ranging from − 0.04 to 0.21 in cross-
validation and − 0.16 to 0.11 in the independent hold-
out test set). Still, while the two published approaches of
the previous edition were more focused on testing and
optimizing different types of machine learning classifiers,
our study focused on evaluating different types of fea-
tures and searching a specific DILI gene signature.
Therefore, the point of view of our work has been very
different and complement previous approaches.
Overall, our results pointed to a mild variation on the
accuracies depending on the samples included in the
training data as well as the feature set used in building
the classifiers, which we attribute to various factors.
First, the training data is limited to dozens of
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compounds with known hepatotoxicity annotation, and
these are too few to get a robust classifier. Second, most
compounds show a toxic effect based on the dosage
(and are otherwise no-DILI), thus a global predictor cat-
egorizing drugs as simply DILI vs no-DILI might not be
realistic. And, third, there is substantial heterogeneity in
the transcriptomics data from CMap. There is also vari-
ation between the results of the testing set and the inde-
pendent hold-out test set, that could be caused by the
latter being unbalanced (as the labels remain hidden).
Still, the variation between the machine learning algo-
rithms (random forest vs gradient boosting machine) is
not appreciable in most cases (see results for gradient
boosting machine in Supplementary Figs. 8–9). This in-
dicates that even though the classifiers are different, the
results are consistent because they depend on the data
rather than on the algorithms. Still, future work would
be required to experimentally validate the predictions of
these models.
Conclusions
In this study, we developed an ensemble learning approach
to investigate the mechanism of the drugs that cause DILI.
We experimented with gene expression data from the
CMap L1000 dataset both alone and in combination with
other types of feature (chemical structure, drug targets).
We observed that selecting a specific gene signature either
using phenotype-gene associations data (DisGeNET) or a
non-parametric test (Wilcoxon test) of differential expres-
sion between DILI and no-DILI samples constituted a bet-
ter feature than the whole landmark genes in CMap.
However, the accuracy of the best performing classifier is
around the 70% mark (minimum 63%, maximum 76%),
stating the limitations of predicting DILI. The results are
very similar to previous publications [8–10, 12]. Addition-
ally, we used the comparison of chemical structures as a
feature to predict DILI-causing drugs, though this did not
improve the accuracy substantially. When comparing the
chemical structures of the drugs with the same DILI-
Concern classification, we observed a large structural diver-
sity among the DILI-Concern groups, reflected in their dis-
similarity of structure. This may explain the limited
accuracy prediction based on chemical structure. Combin-
ing transcriptomics data and chemical structure did not im-
prove the accuracy of the prediction in the testing set,
although this was improved in the independent hold-out
test set. Specifically, the combination of using a DILI associ-
ated gene signature and chemical structures produced re-
sults of accuracy around or less than 70%, but more robust
when they were validated with the independent hold-out
test set. We also used drug-target associations as feature,
obtaining 57% of accuracy in the testing set that improved
to a 70% in the independent hold-out test set. Summariz-
ing, the overarching goal of this work was to evaluate a
range of descriptors to predict DILI employing two com-
monly used classifiers to predict DILI. We have shown the
limitations and advantages of different sets of data paving
the way for future research in this field.
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